Featured Image: Ado-trastuzumab emtansine (Kadcyla; Genentech/Roche), known as T-DM1 during. Courtesy: Genentech/Roche.
Featured Image: Ado-trastuzumab emtansine (Kadcyla; Genentech/Roche), known as T-DM1 during. Courtesy: Genentech/Roche.

The antibody drug conjugate or ADC is a three-component system including a potent cytotoxic anticancer agent linked via a biodegradable linker to an antibody. The antibody binds to specific markers (antigens or receptors) at the surface of the cancer cell. The whole antibody-drug conjugate is then internalized within the cancer cell, where the linker is degraded and the active drug released.

Fig 1: Antibody drug Conjugates are a new class of therapeutics.  They consists of a cytotoxic agent covalently linked to a monoclonal antibody.

ADCs make use of antibodies that are specific to cell surface proteins and are able to offer various advantages over current chemotherapeutics, including improved target specificity and potency.  While this approach is successful in hematological malignancies, it has some limitations in the treatment of solid tumors.

MabPlex
 

The focused delivery of the cytotoxic agent to the tumor cell is designed to maximize the anti-tumor effect of ADCs, while minimizing its normal tissue exposure, potentially leading to an improved therapeutic index. [1]